Health at Scale Awarded Patent for Breakthrough AI Technology for Smart Hyper-Personalized Provider Navigation

Awarded patent by USPTO for technology innovations in AI-guided provider search for primary and specialist care to optimize PCP assignment and drive smart specialist referrals

Health at Scale, the market leader in smart AI-powered technologies to optimize care management, announced today that it has been awarded a patent by the U.S. Patent and Trademark Office for its breakthrough advances in personalized patient-provider matching using machine learning.

Choosing a provider is often the most important decision a patient makes. Health at Scale’s patented technology transforms provider search by empowering patients to find optimal primary and specialist care provider matches specific to their unique individualized health conditions and needs. This represents a significant advancement over current navigation technologies that consider providers in isolation of the patient – and are typically based on ad-hoc reputation scores or process-based metrics that are not correlated with better outcomes.

Health at Scale’s invention uses new AI technologies to score patient-provider matches based on thousands of health factors about a patient and an understanding of which providers have historically done well with similar kinds of patients. This proprietary approach, offering smart hyper-personalized provider navigation to payers, employers, providers and patients, evaluates the best facility, practice and physician choices for each individual’s unique health situation, and enables the creation of deeply personalized networks for the N-of-1. Health at Scale’s novel approach uses advanced machine learning to simultaneously construct and relate information across multiple models that evaluate the best providers for each individual based on a vast number of factors related to the patient, provider, the time and setting.

This patent advances Health at Scale’s mission to re-invent care delivery as a precise and personalized process that is deeply aware of each patient’s unique health characteristics and circumstances at all times. By rethinking the patient-provider matching process, Health at Scale drives improved outcomes, costs, satisfaction, quality and equity, while reducing unnecessary waste and cost in the system.

“Putting each patient’s needs at the center of care management is a core element of our work at Health at Scale. We’re excited to lead the way in reimagining the how patients find providers: as a process that is built around each patient and shows a nuanced understanding and deep empathy for their unique needs in the moment,” said Zeeshan Syed, Health at Scale CEO and formerly a Clinical Associate Professor at Stanford Medicine and an Associate Professor with Tenure in Computer Science at the University of Michigan. “We’re proud of the recognition from the USPTO for our team’s thought-leadership and pioneering contributions in personalized navigation and are committed to continued innovation for the populations we serve.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”